Insider Transactions in Q3 2024 at Syros Pharmaceuticals, Inc. (SYRS)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Payment of exercise price or tax liability
|
Direct |
3,100
-6.23%
|
$6,200
$2.1 P/Share
|
|
Sep 30
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+16.73%
|
-
|
|
Sep 16
2024
|
Richard A Young |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+20.0%
|
-
|
|
Sep 16
2024
|
Srinivas Akkaraju |
BUY
Exercise of conversion of derivative security
|
Direct |
2,667
+22.23%
|
-
|
|
Sep 12
2024
|
Jason Haas Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
45,344
+26.69%
|
$45,344
$1.68 P/Share
|
|
Sep 11
2024
|
Conley Chee President & CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+28.98%
|
$50,000
$1.71 P/Share
|
|
Sep 11
2024
|
Jason Haas Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
19,293
+19.59%
|
$19,293
$1.58 P/Share
|
|
Sep 10
2024
|
Conley Chee President & CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+40.82%
|
$50,000
$1.51 P/Share
|
|
Sep 10
2024
|
Jason Haas Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
35,363
+37.12%
|
$35,363
$1.55 P/Share
|